Man in western Wisconsin dies from injuries after being hit by car while crossing street
The Ellsworth Police Department reported that officers responded to a vehicle versus pedestrian crash around 3:14 p.m. on Thursday near the intersection of Highway 10, Main Street and Beulah Street in Ellsworth.
Man hit by stray bullet while traveling in Wisconsin, deputies investigating
Initial investigation details state that a 2009 Toyota Camry was heading westbound when the driver, 78-year-old Daniel Hayes of Ellsworth, hit a person crossing the street.
The 74-year-old pedestrian was identified as Kenneth Wilson of Ellsworth. Wilson was reportedly crossing through a marked crosswalk at the time of the crash. He was taken to a Minnesota hospital with life-threatening injuries, where he later died.
Wisconsin driver with 3 unrestrained children under age of 5 arrested for OWI after crash
The crash is still under investigation.
No additional details were provided.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
TruBridge Announces Second Quarter 2025 Conference Call to Be Held Friday, August 8, 2025
MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced that it will release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, after the market closes. The Company will host a conference call at 7:30 a.m. Central Time, 8:30 a.m. Eastern Time on Friday, August 8, 2025. To access this interactive teleconference, dial (877) 407-0890 and request connection to the TruBridge earnings conference call. A live broadcast of TruBridge's conference call will also be available online at the Company's investor relations website, The 30-day online replay will be available approximately an hour following the conclusion of the live broadcast. About TruBridge TruBridge proudly supports rural and community hospitals and providers in their efforts to stay strong, independent, and deeply rooted in the communities they serve. Backed by more than 45 years of healthcare experience and trusted by over 1,500 clients nationwide, we offer a mix of technology, services, and strategic expertise — including revenue cycle management, electronic health records (EHR) and analytics — all designed singularly for the realities of rural and community healthcare. With a steadfast commitment to keeping care local, TruBridge helps hospitals flourish as the economic heart of their communities, delivering high-quality, personal care close to home. For more information, visit
Yahoo
4 hours ago
- Yahoo
BrightSpring Health Services, Inc. (BTSG) Q2 Earnings and Revenues Beat Estimates
BrightSpring Health Services, Inc. (BTSG) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +15.79%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.19, delivering a surprise of +137.5%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. BrightSpring Health Services, Inc., which belongs to the Zacks Medical Services industry, posted revenues of $3.15 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.40%. This compares to year-ago revenues of $2.73 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BrightSpring Health Services, Inc. shares have added about 21.3% since the beginning of the year versus the S&P 500's gain of 7.8%. What's Next for BrightSpring Health Services, Inc.? While BrightSpring Health Services, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BrightSpring Health Services, Inc. was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.28 on $3.16 billion in revenues for the coming quarter and $0.90 on $12.29 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Progyny (PGNY), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This provider of fertility and family building benefits is expected to post quarterly earnings of $0.44 per share in its upcoming report, which represents a year-over-year change of +2.3%. The consensus EPS estimate for the quarter has been revised 4.1% lower over the last 30 days to the current level. Progyny's revenues are expected to be $322.5 million, up 6.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BrightSpring Health Services, Inc. (BTSG) : Free Stock Analysis Report Progyny, Inc. (PGNY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 hours ago
- Business Wire
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's management will host an informational webinar on Bio-Rad's Droplet Digital™ PCR (ddPCR™) product portfolio on Tuesday, August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time). The event will include a presentation followed by a Q&A session with analysts hosted by Bio-Rad's President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. To participate, dial (800) 715-9871 within the U.S. or (+1) (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the event, and the accompanying slide presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at A replay of the webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit
